Healthcare // Browsing posts in Healthcare
Novadaq’s SPY Elite: A Solid Technology Facing Moderate Growth Due to Adoption Challenges
Research Question: Will Novadaq’s SPY Elite be widely adopted and drive company growth in 2016? Companies: EPA:MKEA, ETR:SIE, ISRG, NVDQ, TYO:6965 By: David Franklin Click here to download the report (.pdf) Summary of Findings The medical community considers Novadaq Technologies Inc. (NVDQ) to have innovative and interesting tissue perfusion assessment technology in its product line. […]
Zeltiq Aesthetics Idea Proposal (ZLTQ)
Research Question: Can Zeltiq Aesthetics’ CoolSculpting system continue to fend off competitors with similar or superior body contouring products? Report Available: January 15, 2016 Blueshift’s initial research shows ZLTQ investing heavily in sales and marketing, with strong sales results from its CoolSculpting body contouring system. Competing products are coming on strong and some appear to […]
Novadaq Technologies Idea Proposal
Research Question: Will Novadaq’s SPY Elite be widely adopted and drive the company’s growth in 2016? Report Available: Nov. 24, 2015 Blueshift’s initial research shows NVDQ’s sales momentum increasing now that its technology is transitioning into the adoption phase. But its SPY fluorescence imaging systems could still be years away from achieving angiography gold standard status, […]
Blockbuster Sales Not in Store for Depomed’s Nucynta
Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as the company takes on OxyContin among acute pain patients and Lyrica and Cymbalta in neuropathic pain patients? Companies: DEPO, HZNP, JNJ, LLY, PFE, TSE:ENL By: David Franklin Click here to download the report (.pdf) Summary of Findings Depomed Inc.’s (DEPO) Nucynta and Nucynta […]
Abiomed’s Impella Will Drive Growth But Not at Projected 40%
Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Companies: ABMD, STJ By: David Franklin Click here to download the report (.pdf) Summary of Findings The Impella Platform is expected to drive growth for Abiomed Inc. (ABMD) but not at corporate’s 2020 projected sales rate of $1.2 billion to $1.8 billion, […]
Depomed Idea Proposal (DEPO)
Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015 Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]
Seres’ SER-109 Likely Will Be the First Microbiome Therapy to Market
Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to treat Clostridium difficile infections? Companies: ALIOF/VTX:ATLN, MCRB, MRK, NVS, PFE, SHPG, SNY, SYN By: David Franklin Click here to download the report (.pdf) Summary of Findings Seres Therapeutics Inc.’s (MCRB) Phase 2 drug, SER-109, is expected to be the first […]
Scotts Miracle-Gro Idea Proposal (SMG)
Research Question: Will Scotts Miracle-Gro’s entry into the hydroponics/marijuana market spur the company into high-growth mode? Report Available: Oct. 23, 2015 Blueshift’s initial research shows SMG expanding into the hydroponics market, a sector likely to experience double-digit growth for years to come. However, hydroponics’ user base, many of whom grow marijuana, shudder at […]
Abiomed Idea Proposal
Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Report Available: October 14, 2015 Blueshift’s initial research shows ABMD’s Impella utilization rate is increasing faster than many had expected in its Q1. ABMD, a leader in heart support technologies, then issued an aggressive five-year strategy which predicted $1.2 billion to $1.8 billion in […]
Seres Therapeutics Idea Proposal
Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to cure Clostridium difficile infection? Report Available: October 1, 2015 Blueshift’s initial research shows MCRB’s SER-109 garnering much support from Wall Street and the FDA,which should hasten its time to market. Given SER-109’s exceptional 97% cure rate for the infectious CDI, MCRB hopes […]
Copyright © 2015 Blueshift Research, LLC. All rights reserved.
Connect with Us!